Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

DiObex licenses rights to cortisol inhibitors from Cortendo

April 14, 2005

Phase III PolyHeme study cleared to continue

April 14, 2005

Lasofoxifene induces no adverse effects on mood and cognition in postmenopausal women

April 13, 2005

Fosamax Plus D receives FDA approval

April 13, 2005

Novel therapeutic agents for obesity reported by Schering-Plough

April 12, 2005

A transdermal testosterone patch improves androgen deficiency in women with POF / News in Context

April 12, 2005

NPY Y2 receptor is involved in PYY3-36-mediated appetite regulation / News in Context

April 12, 2005

Recent Merck patents describe new agents for the treatment of osteoporosis

April 11, 2005

BioMarin initiates phase III of Phenoptin for PKU

April 11, 2005

Phase III study of VP-002 for central precocious puberty completes enrollment

April 7, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...